İleri evre rahim ağzı kanseri: yeni bakım standardını nasıl yorumlamalıyız?

As pivotal practice-changing studies, the KEYNOTE-826 (KN826) and BEATcc trials provided the opportunity to add immune checkpoint inhibitors (ICPIs) to the combination of platinum-taxane doublet chemotherapy and bevacizumab, which has been the standard of care for advanced cervical cancer for many years. Combination with ICPI represents the current benchmark for the first-line treatment of advanced cervical cancer. However, there are still issues that need to be questioned in terms of precision medicine. Studies that are not limited by the selection criteria of randomized clinical trials, reflect real-life practices, and measure outcomes for larger patient groups with more balanced representation of different subgroups would be valuable.